Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Coulter to Shutter, Relocate Palo Alto Plant to Indianapolis in '08

NEW YORK (GenomeWeb News) — Beckman Coulter will shutter and relocate its plant in Palo Alto, Calif., by the end of 2008 as part of a cost-cutting strategy, the company said today.
 
Beckman said it will relocate the assets from the facility to the Indianapolis area, where the company currently houses other discovery and automation products.  
 
The Palo Alto plant, which employs 220 staffers, develops and manufactures centrifuges for the company’s Discover and Automation segment. It was not immediately clear whether there will be lay-offs.
 
Pam Miller, supply chain vice president, said the move to Indianapolis will allow the company to “aggressively manage our costs” and take “a longer-term view of work force planning.”
 
The company said moving the facility to Indiana will lower its operational costs because of the “favorable local business environment.” Also, the location will enhance the company’s presence in the region and enable Beckman to take advantage of the state’s efforts to “focus on life sciences and advanced manufacturing.”
 
Miller said the decision to leave Palo Alto was difficult because of the “excellent” staff and the company’s “long history in the area.”

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.